{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:10:48Z","timestamp":1791882648631,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10552-022-01646-y","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T17:03:04Z","timestamp":1666717384000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Diversity and transparency in gynecologic oncology clinical trials"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8937-9202","authenticated-orcid":false,"given":"Mary Katherine","family":"Montes de Oca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth P.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Spinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Knochenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Peipert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Severson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakti","family":"Ramkissoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomi F.","family":"Akinyemiju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Previs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"issue":"7126","key":"1646_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/bmj.316.7126.201","volume":"316","author":"B Sibbald","year":"1998","unstructured":"Sibbald B, Roland M (1998) Understanding controlled trials. Why are randomised controlled trials important? BMJ 316(7126):201","journal-title":"BMJ"},{"issue":"8","key":"1646_CR2","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamainternmed.2021.2041","volume":"181","author":"DA Zarin","year":"2021","unstructured":"Zarin DA, Califf RM (2021) Trial reporting and the clinical trials enterprise. JAMA Intern Med 181(8):1131\u20131132","journal-title":"JAMA Intern Med"},{"issue":"24","key":"1646_CR3","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1056\/NEJMc1504513","volume":"372","author":"ML Anderson","year":"2015","unstructured":"Anderson ML, Peterson ED (2015) Compliance with results reporting at clinicaltrials.gov. N Engl J Med 372(24):2370\u20132371","journal-title":"N Engl J Med"},{"issue":"1","key":"1646_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1200\/JOP.2017.025288","volume":"14","author":"N Duma","year":"2018","unstructured":"Duma N et al (2018) Representation of minorities and women in oncology clinical trials: review of the past 14 years. J Oncol Pract 14(1):e1\u2013e10","journal-title":"J Oncol Pract"},{"issue":"22","key":"1646_CR5","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","volume":"291","author":"VH Murthy","year":"2004","unstructured":"Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291(22):2720\u20132726","journal-title":"JAMA"},{"key":"1646_CR6","unstructured":"Institute of Medicine Committee on, E. and S. Legal Issues Relating to the Inclusion of Women in Clinical (1991) In: Mastroianni AC, Faden R, Federman D (eds) Women and health research: ethical and legal issues of including women in clinical studies, vol I. National Academies Press, Washington"},{"key":"1646_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/d41586-018-05049-5","volume":"557","author":"TC Knepper","year":"2018","unstructured":"Knepper TC, McLeod HL (2018) When will clinical trials finally reflect diversity? Nature 557:157\u2013159","journal-title":"Nature"},{"issue":"7","key":"1646_CR8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1089\/jwh.2012.3733","volume":"21","author":"M Coakley","year":"2012","unstructured":"Coakley M et al (2012) Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials. J Womens Health 21(7):713\u2013716","journal-title":"J Womens Health"},{"issue":"1","key":"1646_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/107327480901600108","volume":"16","author":"JE Allard","year":"2009","unstructured":"Allard JE, Maxwell GL (2009) Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. Cancer Control 16(1):53\u201356","journal-title":"Cancer Control"},{"issue":"11","key":"1646_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/jnci\/djt065","volume":"105","author":"RE Bristow","year":"2013","unstructured":"Bristow RE et al (2013) Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst 105(11):823\u2013832","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1646_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ygyno.2013.12.039","volume":"133","author":"Y Collins","year":"2014","unstructured":"Collins Y et al (2014) Gynecologic cancer disparities: a report from the health disparities taskforce of the society of gynecologic oncology. Gynecol Oncol 133(2):353\u2013361","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1646_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ygyno.2011.11.025","volume":"125","author":"M Terplan","year":"2012","unstructured":"Terplan M et al (2012) Have racial disparities in ovarian cancer increased over time? an analysis of SEER data. Gynecol Oncol 125(1):19\u201324","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1646_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/AOG.0000000000004676","volume":"139","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN et al (2022) The changing landscape of gynecologic cancer mortality in the United States. Obstet Gynecol 139(3):440\u2013442","journal-title":"Obstet Gynecol"},{"key":"1646_CR14","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Populations\u2014Total U.S. (1969\u20132020) <Katrina\/Rita Adjustment>\u2014Linked To County Attributes\u2014Total U.S., 1969\u20132020 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released January 2022"},{"issue":"9","key":"1646_CR15","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1158\/1055-9965.EPI-15-0316","volume":"24","author":"ML Cote","year":"2015","unstructured":"Cote ML et al (2015) The growing burden of endometrial cancer: a major racial disparity affecting black women. Cancer Epidemiol Biomark Prev 24(9):1407\u20131415","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1646_CR16","unstructured":"Howlader N et al (2012) SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations) based on November 2011 SEER data submission, posted to the SEER web site. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2009_pops09\/"},{"issue":"2","key":"1646_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ygyno.2015.05.014","volume":"138","author":"J Scalici","year":"2015","unstructured":"Scalici J et al (2015) Minority participation in gynecologic oncology group (GOG) studies. Gynecol Oncol 138(2):441\u2013444","journal-title":"Gynecol Oncol"},{"issue":"12","key":"1646_CR18","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.2105\/AJPH.94.12.2104","volume":"94","author":"T Madison","year":"2004","unstructured":"Madison T et al (2004) Endometrial cancer: socioeconomic status and racial\/ethnic differences in stage at diagnosis, treatment, and survival. Am J Public Health 94(12):2104\u20132111","journal-title":"Am J Public Health"},{"issue":"2","key":"1646_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1006\/gyno.1998.5203","volume":"71","author":"AJ Mundt","year":"1998","unstructured":"Mundt AJ et al (1998) Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy. Gynecol Oncol 71(2):151\u2013158","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1646_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1006\/gyno.1999.5543","volume":"75","author":"MG del Carmen","year":"1999","unstructured":"del Carmen MG et al (1999) Ethnic differences in patterns of care of stage 1A(1) and stage 1A(2) cervical cancer: a SEER database study. Gynecol Oncol 75(1):113\u2013117","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1646_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ygyno.2020.11.031","volume":"160","author":"JY Islam","year":"2021","unstructured":"Islam JY et al (2021) Racial and ethnic disparities in palliative care utilization among gynecological cancer patients. Gynecol Oncol 160(2):469\u2013476","journal-title":"Gynecol Oncol"},{"issue":"14","key":"1646_CR22","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/jnci\/djp175","volume":"101","author":"KS Albain","year":"2009","unstructured":"Albain KS et al (2009) Racial disparities in cancer survival among randomized clinical trials patients of the Southwest oncology Group. J Natl Cancer Inst 101(14):984\u2013992","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"1646_CR23","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1002\/cncr.24482","volume":"115","author":"JH Farley","year":"2009","unstructured":"Farley JH et al (2009) Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin\/paclitaxel: an analysis of gynecologic oncology group trials. Cancer 115(18):4210\u20134217","journal-title":"Cancer"},{"issue":"24","key":"1646_CR24","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","volume":"25","author":"WE Winter 3rd","year":"2007","unstructured":"Winter WE 3rd et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol 25(24):3621\u20133627","journal-title":"J Clin Oncol"},{"key":"1646_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ygyno.2018.04.017","volume":"149","author":"KB Patel","year":"2018","unstructured":"Patel KB et al (2018) Participation in clinical trials may overcome health disparities in the treatment of advanced or recurrent epithelial ovarian cancer. Gynecol Oncol 149:4\u20135","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1646_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1056\/NEJMp2112233","volume":"386","author":"LE Boulware","year":"2022","unstructured":"Boulware LE et al (2022) Combating structural inequities - diversity, equity, and inclusion in clinical and translational research. N Engl J Med 386(3):201\u2013203","journal-title":"N Engl J Med"},{"issue":"19","key":"1646_CR27","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1200\/JCO.22.00754","volume":"40","author":"RA Oyer","year":"2022","unstructured":"Oyer RA et al (2022) Increasing racial and ethnic diversity in cancer clinical trials: an american society of clinical oncology and association of community cancer centers joint research statement. J Clin Oncol 40(19):2163\u20132171","journal-title":"J Clin Oncol"},{"issue":"5","key":"1646_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/OP.21.00257","volume":"17","author":"L Pierce","year":"2021","unstructured":"Pierce L (2021) ASCO\u2019s commitment to addressing equity, diversity, and inclusion of black cancer patients and survivors. JCO Oncol Pract 17(5):255\u2013257","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"1646_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ygyno.2022.01.032","volume":"165","author":"MK Wagar","year":"2022","unstructured":"Wagar MK et al (2022) Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers. Gynecol Oncol 165(1):49\u201352","journal-title":"Gynecol Oncol"},{"issue":"Suppl 7","key":"1646_CR30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/cncr.28575","volume":"120","author":"MS Chen Jr","year":"2014","unstructured":"Chen MS Jr et al (2014) Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials. Cancer 120(Suppl 7):1091\u20131096","journal-title":"Cancer"},{"issue":"4","key":"1646_CR31","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/(SICI)1097-0142(19970815)80:4<816::AID-CNCR21>3.0.CO;2-V","volume":"80","author":"G Parham","year":"1997","unstructured":"Parham G et al (1997) The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women. Cancer 80(4):816\u2013826","journal-title":"Cancer"},{"issue":"8","key":"1646_CR32","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1200\/JCO.2002.08.056","volume":"20","author":"WB Sateren","year":"2002","unstructured":"Sateren WB et al (2002) How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 20(8):2109\u20132117","journal-title":"J Clin Oncol"},{"issue":"10","key":"1646_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870","volume":"5","author":"JM Loree","year":"2019","unstructured":"Loree JM et al (2019) Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol 5(10):e191870","journal-title":"JAMA Oncol"},{"issue":"11","key":"1646_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.33205","volume":"4","author":"CM Aldrighetti","year":"2021","unstructured":"Aldrighetti CM et al (2021) Racial and ethnic disparities among participants in precision oncology clinical studies. JAMA Netw Open 4(11):e2133205","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1646_CR35","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ygyno.2020.03.002","volume":"157","author":"E Awad","year":"2020","unstructured":"Awad E et al (2020) Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity. Gynecol Oncol 157(3):729\u2013732","journal-title":"Gynecol Oncol"},{"issue":"5","key":"1646_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0197-2456(95)00048-8","volume":"16","author":"LS Freedman","year":"1995","unstructured":"Freedman LS et al (1995) Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993\u2013the perspective of NIH clinical trialists. Control Clin Trials 16(5):277\u2013285","journal-title":"Control Clin Trials"},{"key":"1646_CR37","unstructured":"FDA (2012) FDA Administration Safety and Innovation Act (FDASIA), Section 907 Action Plan. https:\/\/www.fda.gov\/RegulatoryInformation\/LawsEnforcedbyFDA\/SignificantAmendmentstotheFDCAct\/FDASIA\/ucm389100.htm"},{"key":"1646_CR38","unstructured":"NIH. Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research. 2017. https:\/\/grants.nih.gov\/grants\/funding\/women_min\/guidelines.htm"},{"issue":"2","key":"1646_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1634\/theoncologist.2012-0423","volume":"18","author":"RL Schilsky","year":"2013","unstructured":"Schilsky RL (2013) Publicly funded clinical trials and the future of cancer care. Oncologist 18(2):232\u2013238","journal-title":"Oncologist"},{"issue":"2","key":"1646_CR40","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.23157","volume":"112","author":"JG Ford","year":"2008","unstructured":"Ford JG et al (2008) Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 112(2):228\u2013242","journal-title":"Cancer"},{"issue":"2","key":"1646_CR41","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1377\/hlthaff.27.2.393","volume":"27","author":"TG McGuire","year":"2008","unstructured":"McGuire TG, Miranda J (2008) New evidence regarding racial and ethnic disparities in mental health: policy implications. Health Aff 27(2):393\u2013403","journal-title":"Health Aff"},{"issue":"7","key":"1646_CR42","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2105\/AJPH.2005.080762","volume":"97","author":"K Armstrong","year":"2007","unstructured":"Armstrong K et al (2007) Racial\/ethnic differences in physician distrust in the United States. Am J Public Health 97(7):1283\u20131289","journal-title":"Am J Public Health"},{"issue":"16","key":"1646_CR43","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1002\/cncr.30702","volume":"123","author":"SJ Katz","year":"2017","unstructured":"Katz SJ et al (2017) Treatment experiences of Latinas after diagnosis of breast cancer. Cancer 123(16):3022\u20133030","journal-title":"Cancer"},{"issue":"6","key":"1646_CR44","first-page":"216","volume":"34","author":"S Williams","year":"2020","unstructured":"Williams S et al (2020) Strategies for overcoming disparities for patients with hematologic malignancies and for improving enrollment on clinical trials. Oncology 34(6):216\u2013223","journal-title":"Oncology"},{"issue":"1","key":"1646_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00432-007-0263-4","volume":"134","author":"M Markman","year":"2008","unstructured":"Markman M, Petersen J, Montgomery R (2008) An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials. J Cancer Res Clin Oncol 134(1):115\u2013118","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"1646_CR46","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ygyno.2015.05.008","volume":"138","author":"BJ Rimel","year":"2015","unstructured":"Rimel BJ et al (2015) A novel clinical trial recruitment strategy for women\u2019s cancer. Gynecol Oncol 138(2):445\u2013448","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1646_CR47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.amjsurg.2011.02.005","volume":"203","author":"DR Holmes","year":"2012","unstructured":"Holmes DR et al (2012) Increasing minority patient participation in cancer clinical trials using oncology nurse navigation. Am J Surg 203(4):415\u2013422","journal-title":"Am J Surg"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-022-01646-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-022-01646-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-022-01646-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T10:09:35Z","timestamp":1674641375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-022-01646-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1007\/s10552-022-01646-y","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"assertion":[{"value":"18 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}